Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
16 January 2017 |
Main ID: |
EUCTR2012-002639-27-BG |
Date of registration:
|
13/03/2013 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A study to assess long-term safety and effectiveness of MT-1303 in subjects who completed the MT-1303-E04 study.
|
Scientific title:
|
A phase II, multicentre study to evaluate the long-term safety and efficacy of MT-1303 in subjects with relapsing-remitting multiple sclerosis who have completed the MT-1303-E04 study |
Date of first enrolment:
|
30/04/2013 |
Target sample size:
|
400 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002639-27 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: no
Randomised: yes
Open:
Single blind: no
Double blind:
Parallel group:
Cross over: no
Other: yes
Other trial design description: This study is a parallel group 2 part study. Part 1 is double-blind; Part 2 is open-label
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
Number of treatment arms in the trial: 3
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Belgium
|
Bosnia and Herzegovina
|
Bulgaria
|
Canada
|
Croatia
|
Czech Republic
|
Finland
|
Germany
|
Hungary
|
Italy
|
Latvia
|
Lithuania
|
Poland
|
Russian Federation
|
Serbia
|
Spain
|
Sweden
|
Switzerland
|
Turkey
|
Ukraine
|
United Kingdom
| | | |
Contacts
|
Name:
|
Clinical Project Manager
|
Address:
|
Dashwood House, 69 Old Broad Street
EC2M 1QS
London
United Kingdom |
Telephone:
|
00442070655000 |
Email:
|
KGreenough@m-pharma.co.uk |
Affiliation:
|
Mitsubishi Pharma Europe Ltd (MPE) |
|
Name:
|
Clinical Project Manager
|
Address:
|
Dashwood House, 69 Old Broad Street
EC2M 1QS
London
United Kingdom |
Telephone:
|
00442070655000 |
Email:
|
KGreenough@m-pharma.co.uk |
Affiliation:
|
Mitsubishi Pharma Europe Ltd (MPE) |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: Completion of the 24-week Treatment Period in MT-1303-E04 as per protocol Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 400 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria: 1. Permanent discontinuation of study medication prior to the End of Treatment (EOT) Visit in MT-1303-E04
2. Newly diagnosed diabetes mellitus during MT-1303-E04
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Relapsing-remitting multiple sclerosis (RRMS) MedDRA version: 18.0
Level: PT
Classification code 10063399
Term: Relapsing-remitting multiple sclerosis
System Organ Class: 10029205 - Nervous system disorders
|
Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
|
Intervention(s)
|
Product Name: MT-1303 Product Code: MT-1303 Pharmaceutical Form: Capsule INN or Proposed INN: MT-1303 Current Sponsor code: MT-1303 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1-
Product Name: MT-1303 Product Code: MT-1303 Pharmaceutical Form: Capsule INN or Proposed INN: MT-1303 Current Sponsor code: MT-1303 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.2-
Product Name: MT-1303 Product Code: MT-1303 Pharmaceutical Form: Capsule INN or Proposed INN: MT-1303 Current Sponsor code: MT-1303 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.4-
|
Primary Outcome(s)
|
Timepoint(s) of evaluation of this end point: Various timepoints throughout the study - please refer to the detailed Time and Events Schedule in the protocol for full details
|
Secondary Objective: • To evaluate the long-term effects of MT-1303 on magnetic resonance imaging (MRI) parameters, clinical outcomes and health-related quality of life in subjects with RRMS • To evaluate the pharmacodynamics of MT-1303 in subjects with RRMS
|
Primary end point(s): Safety Assessments • Adverse events (AEs) • Vital signs • 12-lead electrocardiogram (ECG) • 3-lead Holter ECG monitoring • Routine safety laboratory assessments • Physical examination • Optical coherence tomography (OCT)
|
Main Objective: To evaluate the long-term safety and tolerability of MT-1303 in subjects with RRMS
|
Secondary Outcome(s)
|
Secondary end point(s): Clinical Efficacy Endpoints:
• Annualised Relapse Rate (ARR)
• Time to first confirmed relapse
• Proportion of subjects who remain relapse-free at End of Treatment (EOT)
• Change from baseline in total Expanded Disability Status Scale (EDSS) score at EOT
• Change from baseline in total Multiple Sclerosis Functional Composite (MSFC) score at EOT
MRI Endpoints:
• Number of MRI Gd-enhanced T1-weighted lesions
• Number and volume of new or enlarged T2-weighted lesions
• Change and percent change in brain volume at EOT
• Magnetisation Transfer Ratio (MTR) related endpoints will be explored. Details to be specified in the Statistical Analysis Plan (SAP) (selected centres only)
Pharmacodynamic Endpoints:
• Lymphocyte counts
• Lymphocyte subsets (selected centres only)
Subject-reported Endpoints:
• Change from baseline in MSQOL-54 at EOT.
|
Timepoint(s) of evaluation of this end point: Various timepoints throughout the study - please refer to the detailed Time and Events Schedule in the protocol for full details
|
Secondary ID(s)
|
MT-1303-E05
|
2012-002639-27-GB
|
Source(s) of Monetary Support
|
Mitsubishi Tanabe Pharma Corporation (MTPC)
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|